tailieunhanh - Báo cáo y học: "Review of "The Twelfth West Coast Retrovirus Meeting" and "The Twenty-third Annual Symposium on Nonhuman Primate Models for AIDS""

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Review of "The Twelfth West Coast Retrovirus Meeting" and "The Twenty-third Annual Symposium on Nonhuman Primate Models for AIDS". | AIDS Research and Therapy BioMed Central Review Open Access Review of The Twelfth West Coast Retrovirus Meeting and The Twenty-third Annual Symposium on Nonhuman Primate Models for AiDs J Scott Cairns Address Henry M Jackson Foundation Mercer Island WA USA Email J Scott Cairns - scairns@ Corresponding author Published II January 2006 Received 06 December 2005 AIDS Research and Therapy 2006 3 1 doi 1742-6405-3-1 Accepted 1 1 January 2006 This article is available from http content 3 1 1 2006 Cairns licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Two recent meetings held on the west coast of the USA highlighted current work being done in the field of retrovirology and AIDS. The meetings The Twelfth West Coast Retrovirus Meeting Palm Springs CA October 6-8 2005 and the Twenty-third Annual Symposium on Nonhuman Primate Models for AIDS Portland OR September 21-24 covered a broad range of topics. The highlights covered here are not meant to be inclusive but reflect presentations of interest in the identification and development of new HIV therapies and the role played by animal models in their development. New inhibitors To date the only commercially available anti-retroviral drugs target three viral proteins HIV reverse transcriptase protease and gp41. In view of the emergence of drug resistance and toxicities associated with the use of current retroviral inhibitors the need remains for new drugs whose resistance profiles do not overlap with the current arsenal. An obvious way to circumvent this problem is with drugs that target other critical viral proteins. Integrase inhibitors and chemokine receptor inhibitors are currently being tested in late stage clinical trials. While